PCRX FINANCIAL STATEMENTS

Pacira BioSciences, Inc. — balance sheet, income statement and cash flow trends

PCRXPacira BioSciences, Inc.

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue734.9 M $+4.6%

Gross Profit583 M $+6.9%

Operating Income22.7 M $—

EBITDA118.4 M $+322.5%

Net Income5.1 M $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PCRX	4.6%	79.3%	16.1%	0.7%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
BHC	-9.9%	75.9%	60.0%	-13.5%
HLN	-26.7%	61.5%	25.2%	12.6%
TLRY	3.8%	27.7%	-156.2%	-158.8%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
PCRX	4.6%	79.3%	16.1%	0.7%
AMPH	-1.1%	47.3%	26.6%	11.0%
PAHC	26.0%	32.5%	15.0%	6.3%
XERS	41.5%	81.6%	14.7%	3.8%
COLL	19.9%	60.7%	76.6%	9.4%
IRWD	13.8%	99.6%	57.3%	28.3%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity653.9 M $54%
Current Liabilities108.8 M $9%
Long-term Liabilities445.9 M $37%

Key Figures

YoY change

Total Assets1.2 B $-23.8%

Total Liabilities554.6 M $-29.6%

Total Equity653.9 M $-18.1%

Cash & ST Investments202.2 M $-59.0%

Total Debt411.2 M $-35.4%

Net Debt266.9 M $-24.4%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PCRX	4.73	62.9%	1.77	54.1%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
BHC	1.32	-1,010.0%	3.71	-8.4%
HLN	0.92	52.3%	3.50	50.3%
TLRY	2.79	20.4%	-0.07	75.1%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
PCRX	4.73	62.9%	1.77	54.1%
AMPH	3.85	88.7%	2.05	46.9%
PAHC	3.17	217.6%	3.15	25.0%
XERS	2.12	286.9%	-1.61	3.3%
COLL	1.71	258.6%	0.63	18.9%
IRWD	1.41	-275.1%	1.82	-50.0%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow142.2 M $-19.1%

Capital Expenditures9.5 M $-41.8%

Free Cash Flow132.7 M $-16.7%

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PCRX	19.4%	18.1%	1.3%	2,767.9%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
BHC	16.2%	11.3%	4.9%	-119.7%
HLN	12.5%	11.3%	1.2%	99.0%
TLRY	-5.6%	-8.3%	3.8%	3.5%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
PCRX	19.4%	18.1%	1.3%	2,767.9%
AMPH	23.4%	18.8%	4.7%	213.2%
PAHC	4.4%	0.9%	3.6%	69.4%
XERS	15.4%	15.0%	0.4%	404.1%
COLL	41.6%	41.4%	0.2%	441.7%
IRWD	31.0%	31.0%	0.0%	109.8%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on PCRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.